Investigational drug · Phase 3
SG301
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "SG301"
First trial start
2024
Jun 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SG301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus (SLE)
- Relapsed/Refractory Multiple Myeloma
- Antibody Mediated Rejection
Approved drugs for the same conditions: Multiple myeloma · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SG301" as an intervention, largest first.
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsPivotal-lookingRecruiting
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT06508983 · 360 participants (planned) · Start Jun 14, 2024 · Primary completion Mar 31, 2027
Drug: SG301 Injection; SG301 placebo and 2 more · For: Relapsed/Refractory Multiple Myeloma
Sites: Beijing, China; Guangzhou, China; Luoyang, China · 12 sites in all
- To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusPivotal-lookingRecruiting
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT07447986 · 120 participants (planned) · Start Mar 26, 2026 · Primary completion Sep 30, 2027
Drug: SG301 SC Injection; SG301 SC Injection and 1 more · For: Systemic Lupus Erythematosus (SLE)
Sites: Beijing, China; Chongqing, China; Xiamen, China · 40 sites in all
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruiting
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT04684108 · 61 participants · Start Nov 4, 2021 · Primary completion Jun 30, 2024
Drug: SG301 · For: Relapsed or Refractory Multiple Myeloma; Hematological Malignancy
Sites: Bengbu, China; Beijing, China; Shenzhen, China · 14 sites in all
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT07710248 · 60 participants (planned) · Start Jun 11, 2026 · Primary completion May 17, 2027
Drug: low dose group; high dose group and 1 more · For: Primary Immune Thrombocytopenia
Sites: Fuzhou, China; Guangzhou, China; Liuzhou, China · 22 sites in all
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT06144710 · 48 participants · Start Nov 10, 2023 · Primary completion Jan 7, 2026
Drug: SG301 SC Injection; SG301 SC Placebo · For: Systemic Lupus Erythematosus (SLE)
Sites: Bengbu, China; Fuzhou, China; Xiamen, China · 10 sites in all
Mao JianhuaAcademic, hospital or other
NCT07087314 · 30 participants (planned) · Start Aug 25, 2025 · Primary completion Jul 9, 2028
Drug: SG301 Subcutaneous injection · For: Nephrotic Syndrome in Children
Sites: Hangzhou, China
- Study of SG301 for Renal AMR After TransplantationNot yet recruiting
Hangzhou Sumgen Biotech Co., Ltd.Industry
NCT07764627 · 10 participants (planned) · Start Dec 1, 2026 · Primary completion Mar 31, 2027
Drug: SG301 Injection · For: Antibody Mediated Rejection
Sites: Guangzhou, China; Nanning, China; Zhengzhou, China · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Characterization of insecticide resistance across aquatic arthropods of the California Sacramento River watershed.
Poynton HC, Polunina-Proulx IA, Broughal T, et al. · Environ Pollut 2026
Also in development for Systemic Lupus Erythematosus (SLE)
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- EnpatoranM5049, M5049 dosePhase 35 trials
EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- ESG206ESG206-2Phase 23 trials
Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome
- BCMA-CD19-IL-15Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
- C-CAR168Phase 22 trials
AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.